Analysis of non-adhesive pathogenic mechanisms of BAD1 on Blastomyces dermatitidis

References

• Harvey RP, Schmid ES, Carrington CC, Stevens DA. Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis 1978; 117: 695–703
   PubMedGoogle Scholar
• Wüthrich M, Chang WL, Klein BS. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis. Infect Immun 1998; 66: 5443–5449
   PubMedGoogle Scholar
• Brandhorst TT, Wüthrich M, Warner T, Klein B. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J Exp Med 1999; 189: 1207–1216
   PubMed Web of Science ®Google Scholar
• Newman SL, Chaturvedi S, Klein BS. The WI-1 antigen of Blastomyces dermatitidis yeasts mediates binding to human macrophage CD11b/CD18 (CR3) and CD14. J Immunol 1995; 154: 753–761
   PubMed Web of Science ®Google Scholar
• Galan JE, Collmer A. Type III secretion machines: Bacterial devices for protein delivery into host cells. Science 1999; 284: 1322–1328
   PubMed Web of Science ®Google Scholar
• Brandhorst T, Wüthrich M, Finkel-Jimenez B, Klein B. A C-terminal EGF-like domain governs BAD1 localization to the yeast surface and fungal adherence to phagocytes, but is dispensable in immune modulation and pathogenicity of Blastomyces dermatitidis. Mol Microbiol 2003; 48: 53–65
   PubMed Web of Science ®Google Scholar
• Finkel-Jimenez B, Wüthrich M, Brandhorst T, Klein BS. The WI-1 adhesin blocks phagocyte TNF-alpha production, imparting pathogenicity on Blastomyces dermatitidis. J Immunol 2001; 166: 2665–2673
   PubMed Web of Science ®Google Scholar
• Worsham PL, Goldman WE. Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores. J Med Vet Mycol 1988; 26: 137–143
   PubMedGoogle Scholar
• Hilger AE, Danley DL. Alteration of polymorphonuclear leukocyte activity by viable Candida albicans. Infect Immun 1980; 27: 714–720
   PubMedGoogle Scholar
• Kruisbeck, AM. Preparation of cell suspensions from spleen, thymus, and lymph node. In:. JE Coligan, Kruisbeck, AM, Margulies, DH, Strober, W, (eds). Current Protocols in Immunology. New York, John Wiley & Sons Inc., 1992, 3.1.3.
   Google Scholar
• Finkel-Jimenez B, Wüthrich M, Klein BS. BAD1, an essential virulence factor of Blastomyces dermatitidis, suppresses host TNF-alpha production through TGF-beta-dependent and -independent mechanisms. J Immunol 2002; 168: 5746–5755
   PubMed Web of Science ®Google Scholar
• Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. John Wiley & Sons, New York 1993; 611–613
   Google Scholar
• Collet D. Modeling Survival Data in Medical Research. Chapman-Hall, London 1994
   Google Scholar
• Garner RE, Hudson JA. Intravenous injection of Candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum. Infect Immun 1996; 64: 4561–4566
   PubMed Web of Science ®Google Scholar
• Lechner AJ, Tredway TL, Brink DS, Klein CA, Matuschak GM. Differential systemic and intrapulmonary TNF-alpha production in Candida sepsis during immunosuppression. Am J Physiol 1992; 263: 526–535
   Google Scholar
• Huffnagle GB, Toews GB, Burdick MD, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157: 4529–4536
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137–161
   PubMed Web of Science ®Google Scholar
• Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism. Science 1992; 257: 545–548
   PubMed Web of Science ®Google Scholar
• Barral A, Barral-Netto M, Yong EC, et al. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci USA 1993; 90: 3442–3446
   PubMed Web of Science ®Google Scholar
• Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE. The importance of TGF-beta in murine visceral leishmaniasis. J Immunol 1998; 161: 6148–6155
   PubMedGoogle Scholar
• Gomes NA, Gattass CR, Barreto-De-Souza V, Wilson ME, DosReis GA. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J Immunol 2000; 164: 2001–2008
   PubMedGoogle Scholar
• Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 1998; 188: 1849–1857
   PubMed Web of Science ®Google Scholar
• Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995; 270: 932–933
   PubMed Web of Science ®Google Scholar
• Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541–2550
   PubMed Web of Science ®Google Scholar
• Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance?. J Immunol 1997; 158: 1989–1993
   PubMed Web of Science ®Google Scholar
• Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445–450
   PubMed Web of Science ®Google Scholar